A single subcutaneous dose of the anti-IL-15 antibody significantly preserved intestinal villous architecture during a six-week gluten challenge.
Key Takeaways
- Teva reported positive topline results from an ongoing randomized Phase 2a study of TEV-‘408, an investigational anti-interleukin-15 (IL-15) monoclonal antibody, in adults with celiac disease.
- TEV-‘408 significantly reduced gluten-induced deterioration in villous height-to-crypt depth ratio versus placebo, meeting the study’s primary endpoint.
- TEV-‘408 also markedly limited the increase in intestinal intraepithelial lymphocytes and was well tolerated with no emerging safety signals reported to date. (Teva Phase 2a)
Data Snapshot
| Item | Details |
|---|---|
| Drug | TEV-‘408 |
| Company | Teva |
| Mechanism | Anti-IL-15 monoclonal antibody |
| Indication | Celiac disease |
| Phase | Phase 2a |
| Participants | 50 adults |
| Dosing | Single subcutaneous dose |
| Challenge | Six-week daily gluten challenge |
| Primary endpoint | Change in villous height-to-crypt depth ratio |
| TEV-‘408 | −0.43 |
| Placebo | −0.88 |
| Treatment difference | 0.45; 95% CI 0.06–0.84; p<0.05 |
| IEL change | +0.37 vs +27.60 placebo |
| Safety | No emerging safety signals |
In an ongoing randomized Phase 2a study of 50 adults with celiac disease, a single subcutaneous dose of Teva’s anti-IL-15 antibody TEV-‘408 significantly reduced gluten-induced intestinal damage versus placebo after a six-week daily gluten challenge. (Teva Phase 2a)
What Happened
On September 2, 2026, Teva reported that TEV-‘408, an investigational anti-IL-15 monoclonal antibody, met the primary endpoint in an ongoing randomized Phase 2a study in 50 adults with celiac disease.
Participants were following a gluten-free diet and had minimal intestinal damage at baseline. They received a single subcutaneous dose of TEV-‘408 or placebo, followed two weeks later by a six-week daily gluten challenge.
At week 8, the least-squares mean change in villous height-to-crypt depth ratio (Vh:Cd) was −0.43 with TEV-‘408 versus −0.88 with placebo, corresponding to a treatment difference of 0.45 (95% CI 0.06–0.84; p<0.05). A smaller decline in Vh:Cd indicates better preservation of intestinal villous architecture.
The biological readout was also notable. Intraepithelial lymphocyte density increased by 0.37 with TEV-‘408 versus 27.60 with placebo, for a treatment difference of −27.23 (95% CI −39.67 to −14.79).
Teva also reported lower gastrointestinal symptom scores versus placebo and stated that TEV-‘408 was well tolerated with no emerging safety signals at the time of the topline analysis.
Fierce Biotech independently highlighted the result as an important proof-of-concept for Teva’s autoimmune pipeline, while Reuters reported that Teva shares rose nearly 3% in early trading following the readout. (Fierce Biotech, Reuters)
Why It Matters
Celiac disease is an immune-mediated disease in which gluten exposure triggers inflammation and damages the small intestine.
Celiac disease currently has no approved pharmacologic therapy in the United States, and treatment remains based on strict adherence to a gluten-free diet. (FDA gluten guidance)
That leaves an important unmet need for therapies that could reduce intestinal damage caused by accidental or unavoidable gluten exposure.
TEV-‘408 targets IL-15, a cytokine involved in the activation and survival of cytotoxic intraepithelial lymphocytes that can damage intestinal epithelial cells.
The therapeutic concept is straightforward:
TEV-‘408 blocks IL-15 → cytotoxic IEL activation decreases → epithelial injury decreases → intestinal villous architecture is better preserved.
The Phase 2a data are notable because the tissue-level results align with the proposed mechanism: TEV-‘408 limited both IEL expansion and deterioration of villous architecture during a controlled gluten challenge.

The figure above visualizes this mechanism, showing how IL-15 blockade can reduce cytotoxic IEL activity and help protect intestinal villous structure during gluten exposure.
BP View
The strongest part of this Phase 2a result is not simply that TEV-‘408 reached statistical significance. It is the mechanistic consistency between the drug’s target and the trial’s tissue-level endpoints.
TEV-‘408 is designed to inhibit IL-15-driven immune activity, and the study showed both a markedly smaller increase in intraepithelial lymphocytes and significantly better preservation of intestinal villous architecture. That gives Teva early biological proof-of-concept beyond symptom improvement alone.
The opportunity may also extend beyond celiac disease. TEV-‘408 is being evaluated in vitiligo, and Teva has positioned the program as a potential “pipeline-in-a-product” based on the possibility that IL-15 blockade could be relevant across multiple immune-mediated diseases. (Teva pipeline)
The limitation is equally clear. This remains an ongoing Phase 2a study of only 50 adults using a single dose and a controlled six-week gluten challenge. Larger and longer studies still need to establish durability, real-world symptom benefit, long-term safety and whether the observed histologic protection remains meaningful under everyday accidental gluten exposure.
In my view, TEV-‘408 has now cleared an important proof-of-mechanism hurdle. The next question is whether selective IL-15 blockade can translate intestinal histology protection into a practical therapy that materially reduces the burden of living with celiac disease.

Related Post
For another recent example of selective immune signaling control, read my previous analysis of Novartis’ remibrutinib Phase 3 results in relapsing multiple sclerosis.
About BP
Biopharma Perspective (BP) explains global biopharma news through strategic, clinical and market perspectives.
Have a different view on this analysis or something you’d like to discuss? Leave a comment — I’d be happy to hear your thoughts.


Leave a Reply